Patent ID: 7026314

Claim:
A compound of the formula (I): wherein R 1 is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, thiomethoxy, —NHA, —NA 2 , —NHC(═O)A, aminocarbonyl, —C(═O)NHA, —C(═O)NA 2 , halogen, hydroxy, —OA, cyano or aryl; A is optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-6 cycloalkyl; R 2 is piperazinyl; R 3 is independently at each position represented by —H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-6 cycloalkyl; n is 2, 3 or 4; P is a heterocyclic ring; R 6 is —H or methyl; Y is —C(═O)NH—, —C(═O)NA—, —C(═O)N(A)—, —NHC(═O)—, —C(═S)NH—, —CH 2 NH—, —C(═O)—, —C(═O)CH 2 —, —CH 2 C(═O)—, —C(═O)-piperazinyl-, —NAC(═O)—, —C(═S)N(A)—, —CH 2 NA—, —NACH 2 — or a 5-membered heterocyclic, R 7 is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally substituted by one or more substituents selected from R 8 –R 9 and R 10 ; wherein R 7 is connected to Y either by a single bond or by a ring fusion; R 8 is —CH 2 —, —C(═O)—, —SO 2 —, —SO 2 NH—, —C(═O)NH—, —O—, —S—, —S(═O)—, a single bond as tether from R 7 to R 9 , a five membered heterocyclic connected to R 7 by a ring fusion or single bond as tether; R 9 is optionally substituted heterocycle, optionally substituted aryl, optionally substituted piperazinyl-R11, optionally substituted morpholinyl-R11, optionally substituted thiomorpholinyl, or —C(═O)A; R 10 is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen, —C(═O)NH 2 , thiomethoxy, —NHA, —NA 2 , —NHC(═O)A, —C(═O)NHA, —C(═O)NA 2 or OA; R 11 is —H, alkyl, —A, —SO 2 A, —SO 2 NH 2 , —SO 2 NHA, —SO 2 NA 2 , —SO 2 NHAR 9 , —C(═O)R 9 , -alkylR 9 , —C(═O)A, —C(═O)NH 2 , —C(═O)NHA, —C(═O)NA 2 or —C(═O)OA; or a pharmaceutically acceptable salt of said compound.